[go: up one dir, main page]

SI3448846T1 - Sinteza indazolov - Google Patents

Sinteza indazolov

Info

Publication number
SI3448846T1
SI3448846T1 SI201730851T SI201730851T SI3448846T1 SI 3448846 T1 SI3448846 T1 SI 3448846T1 SI 201730851 T SI201730851 T SI 201730851T SI 201730851 T SI201730851 T SI 201730851T SI 3448846 T1 SI3448846 T1 SI 3448846T1
Authority
SI
Slovenia
Prior art keywords
indazoles
synthesis
Prior art date
Application number
SI201730851T
Other languages
English (en)
Inventor
Tobias Thaler
Johannes Platzek
Nicolas Guimond
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of SI3448846T1 publication Critical patent/SI3448846T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI201730851T 2016-04-29 2017-04-25 Sinteza indazolov SI3448846T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167652 2016-04-29
EP17718558.4A EP3448846B1 (en) 2016-04-29 2017-04-25 Synthesis of indazoles
PCT/EP2017/059744 WO2017186689A1 (en) 2016-04-29 2017-04-25 Synthesis of indazoles

Publications (1)

Publication Number Publication Date
SI3448846T1 true SI3448846T1 (sl) 2021-09-30

Family

ID=55860769

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201731443T SI3448848T1 (sl) 2016-04-29 2017-04-25 Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida
SI201730851T SI3448846T1 (sl) 2016-04-29 2017-04-25 Sinteza indazolov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201731443T SI3448848T1 (sl) 2016-04-29 2017-04-25 Polimorfna oblika N-(6-(2-hidroksipropan-2-il)-2-(2-(metilsulfonil)etil)-2H-indazol-5-il) -6-(trifluormetil)piridin-2-karboksamida

Country Status (42)

Country Link
US (2) US10759758B2 (sl)
EP (4) EP4275755A3 (sl)
JP (2) JP7068188B2 (sl)
KR (2) KR102373017B1 (sl)
CN (3) CN109415340B (sl)
AR (1) AR108245A1 (sl)
AU (2) AU2017257211B2 (sl)
CA (1) CA3022324C (sl)
CL (2) CL2018003087A1 (sl)
CO (2) CO2018011622A2 (sl)
CU (1) CU20180131A7 (sl)
DK (2) DK3448846T3 (sl)
DO (1) DOP2018000237A (sl)
EA (2) EA201892415A1 (sl)
EC (1) ECSP18081437A (sl)
ES (2) ES2966772T3 (sl)
FI (1) FI3448848T3 (sl)
GE (1) GEP20217214B (sl)
HR (2) HRP20211072T1 (sl)
HU (2) HUE056460T2 (sl)
IL (2) IL262414B2 (sl)
JO (2) JOP20170099B1 (sl)
LT (2) LT3448848T (sl)
MA (1) MA44759B1 (sl)
MX (2) MX383591B (sl)
MY (2) MY190319A (sl)
NI (1) NI201800112A (sl)
PE (1) PE20190107A1 (sl)
PH (1) PH12018502289B1 (sl)
PL (2) PL3448848T3 (sl)
PT (2) PT3448848T (sl)
RS (2) RS62112B1 (sl)
SA (1) SA518400333B1 (sl)
SG (2) SG11201808108XA (sl)
SI (2) SI3448848T1 (sl)
SV (1) SV2018005775A (sl)
TN (1) TN2018000352A1 (sl)
TW (2) TWI657084B (sl)
UA (2) UA124103C2 (sl)
UY (2) UY37216A (sl)
WO (2) WO2017186689A1 (sl)
ZA (1) ZA201808057B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
LT3448849T (lt) 2016-04-29 2020-09-25 Bayer Pharma Aktiengesellschaft Indazolo sintezė
MA44759B1 (fr) 2016-04-29 2024-01-31 Bayer Pharma AG Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
JP7099966B2 (ja) * 2016-06-01 2022-07-12 バイエル・ファルマ・アクティエンゲゼルシャフト 自己免疫疾患を治療および予防するための２－置換インダゾールの使用
CN120531733A (zh) 2016-06-01 2025-08-26 礼蓝动物保健有限公司 用于治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
EP3816164B9 (en) 2018-06-25 2024-07-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Isothiazolo[5,4-d]pyrimidine compound as irak4 inhibitor
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
CN114469979B (zh) * 2021-12-15 2024-04-09 安徽贝克生物制药有限公司 一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AU2007213452A1 (en) 2006-02-10 2007-08-16 Biomarin Iga Limited Treatment of Duchenne muscular dystrophy
WO2008001883A1 (en) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
KR20090049076A (ko) 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
US20120196824A1 (en) 2009-10-09 2012-08-02 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
JP6007189B2 (ja) 2010-12-20 2016-10-12 メルク セローノ ソシエテ アノニム Ｉｒａｋ阻害剤としてのインダゾリルトリアゾール誘導体
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP2016535097A (ja) * 2013-11-08 2016-11-10 アイティーオス セラペウティクス ４−（インドール−３−イル）−ピラゾール誘導体、医薬組成物および使用のための方法
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3288558B1 (en) * 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
US20180201609A1 (en) 2015-07-15 2018-07-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
MA44759B1 (fr) 2016-04-29 2024-01-31 Bayer Pharma AG Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
LT3448849T (lt) 2016-04-29 2020-09-25 Bayer Pharma Aktiengesellschaft Indazolo sintezė
JP7099966B2 (ja) 2016-06-01 2022-07-12 バイエル・ファルマ・アクティエンゲゼルシャフト 自己免疫疾患を治療および予防するための２－置換インダゾールの使用
CN120531733A (zh) 2016-06-01 2025-08-26 礼蓝动物保健有限公司 用于治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑

Also Published As

Publication number Publication date
JOP20170099B1 (ar) 2022-03-14
IL262414B2 (en) 2023-10-01
NI201800112A (es) 2019-08-29
HRP20231454T1 (hr) 2024-03-01
MY190319A (en) 2022-04-13
ECSP18081437A (es) 2018-11-30
AU2017256626B2 (en) 2021-05-27
TW201738232A (zh) 2017-11-01
PT3448846T (pt) 2021-08-19
AU2017257211B2 (en) 2021-05-27
EA201892415A1 (ru) 2019-05-31
KR20180137497A (ko) 2018-12-27
CA3022324A1 (en) 2017-11-02
AU2017256626A1 (en) 2018-10-11
UA123169C2 (uk) 2021-02-24
WO2017186703A1 (en) 2017-11-02
EP3448846A1 (en) 2019-03-06
ZA201808057B (en) 2023-05-31
DOP2018000237A (es) 2018-11-15
FI3448848T3 (fi) 2023-12-21
JP6954924B2 (ja) 2021-10-27
CN109415340A (zh) 2019-03-01
MX380032B (es) 2025-03-11
AR108245A1 (es) 2018-08-01
CN109071489B (zh) 2020-07-10
BR112018072242A2 (pt) 2019-04-09
EP4275755A3 (en) 2023-12-27
DK3448846T3 (da) 2021-08-16
EA201892430A1 (ru) 2019-05-31
UY37215A (es) 2017-11-30
HRP20211072T1 (hr) 2021-10-01
ES2966772T3 (es) 2024-04-24
EA038035B1 (ru) 2021-06-25
BR112018072246A2 (pt) 2019-02-12
MX2018013234A (es) 2019-02-13
EP3448846B1 (en) 2021-05-26
US10501417B2 (en) 2019-12-10
PE20190107A1 (es) 2019-01-15
LT3448848T (lt) 2023-11-27
HUE056460T2 (hu) 2022-02-28
IL262414A (en) 2018-12-31
JP7068188B2 (ja) 2022-05-16
CO2018011644A2 (es) 2018-11-13
JOP20170100B1 (ar) 2022-03-14
CA3022332A1 (en) 2017-11-02
CA3022324C (en) 2024-10-29
CL2018003087A1 (es) 2019-02-22
JP2019514922A (ja) 2019-06-06
EP3448848A1 (en) 2019-03-06
MA44759A (fr) 2019-03-06
AU2017257211A1 (en) 2018-10-11
KR102373017B1 (ko) 2022-03-11
MA44759B1 (fr) 2024-01-31
UY37216A (es) 2018-06-29
TWI649314B (zh) 2019-02-01
PT3448848T (pt) 2024-01-02
SA518400333B1 (ar) 2022-06-05
TW201738230A (zh) 2017-11-01
NZ746469A (en) 2023-08-25
UA124103C2 (uk) 2021-07-21
NZ746526A (en) 2023-08-25
PH12018502289A1 (en) 2019-07-15
EP3448848B1 (en) 2023-09-27
CN113185457A (zh) 2021-07-30
HUE064389T2 (hu) 2024-03-28
PL3448848T3 (pl) 2024-03-11
LT3448846T (lt) 2021-07-26
US20190112270A1 (en) 2019-04-18
CL2018003088A1 (es) 2019-01-25
RS64928B1 (sr) 2023-12-29
SI3448848T1 (sl) 2024-01-31
KR102373220B1 (ko) 2022-03-11
MX383591B (es) 2025-03-14
EP4275754A3 (en) 2023-12-27
PH12018502289B1 (en) 2022-04-06
CN109415340B (zh) 2021-10-12
CN109071489A (zh) 2018-12-21
GEP20217214B (en) 2021-01-25
TWI657084B (zh) 2019-04-21
EP4275755A2 (en) 2023-11-15
ES2883298T3 (es) 2021-12-07
RS62112B1 (sr) 2021-08-31
US10759758B2 (en) 2020-09-01
MX2018013235A (es) 2019-02-13
EP4275754A2 (en) 2023-11-15
CO2018011622A2 (es) 2018-11-22
PL3448846T3 (pl) 2021-12-20
IL262659B (en) 2021-05-31
JP2019514923A (ja) 2019-06-06
IL262659A (en) 2018-12-31
IL262414B1 (en) 2023-06-01
WO2017186689A1 (en) 2017-11-02
US20190106407A1 (en) 2019-04-11
TN2018000352A1 (en) 2020-06-15
KR20180137496A (ko) 2018-12-27
CU20180131A7 (es) 2019-06-04
MY187184A (en) 2021-09-09
SG11201808108XA (en) 2018-10-30
SG11201808566WA (en) 2018-11-29
SV2018005775A (es) 2019-02-07
DK3448848T3 (da) 2023-12-18

Similar Documents

Publication Publication Date Title
ZA201808057B (en) Synthesis of indazoles
IL273230A (en) Preparation of carbamoylpyridone-polycyclic compounds
IL262413B (en) Synthesis of indazoles
SG10202111790YA (en) Synthesis of omecamtiv mecarbil
IL295588A (en) Synthesis of the Lichondrins
GB201416303D0 (en) Speech synthesis
SMT202100551T1 (it) Derivati di sobetirome
EP3500286A4 (en) N-CARBOXYANHYDRIDE-BASED ELAMIPRETIDE SCALE SYNTHESIS
GB2544486B (en) Synthesis of Ammonia
GB201512678D0 (en) Methods of chemical synthesis
GB201621817D0 (en) Methods of chemical synthesis
GB201513979D0 (en) Synthesis of benzodiazepine derivatives
GB201405253D0 (en) Speech synthesis
IL263363A (en) Polymorph of nintedanib
GB2553887B (en) Arrangement of line connections
GB201721386D0 (en) Chrondogy of time-wave
HK40007680A (en) N-carboxyanhydride-based-scale synthesis of elamipretide
ZA201500269B (en) Wall-mounting of bathroom accessories